| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
,§
*
Cytokine Molecular Mechanisms Section, Laboratory of Molecular Immunoregulation, Division of Basic Sciences, and
Laboratory of Experimental Immunology, National Cancer Institute, Frederick, MD 21702;
Intramural Research Support Program, Science Applications International Corporation (SAIC)-Frederick, Frederick Cancer Research and Development Center, Frederick, MD 21702; and
§
Department of Integrative Biology, Pharmacology, and Physiology, University of Texas, Houston, TX 77030
AG-490 is a member of the tyrphostin family of tyrosine kinase inhibitors. While AG-490 has been considered to be a Janus kinase (JAK)2-specific inhibitor, these conclusions were primarily drawn from acute lymphoblastic leukemia cells that lack readily detectable levels of JAK3. In the present study, evidence is provided that clearly demonstrates AG-490 potently suppresses IL-2-induced T cell proliferation, a non-JAK2-dependent signal, in a dose-dependent manner in T cell lines D10 and CTLL-2. AG-490 blocked JAK3 activation and phosphorylation of its downstream counterpart substrates, STATs. Inhibition of JAK3 by AG-490 also compromised the Shc/Ras/Raf/mitogen-activated protein kinase (MAPK) signaling pathways as measured by phosphorylation of Shc and extracellular signal-related kinase 1 and 2 (ERK1/2). AG-490 effectively inhibited tyrosine phosphorylation and DNA binding activities of several transcription factors including STAT1, -3, -5a, and -5b and activating protein-1 (AP-1) as judged by Western blot analysis and electrophoretic mobility shift assay. These data suggest that AG-490 is a potent inhibitor of the JAK3/STAT, JAK3/AP-1, and JAK3/MAPK pathways and their cellular consequences. Taken together, these findings support the notion that AG-490 possesses previously unrecognized clinical potential as an immunotherapeutic drug due to its inhibitory effects on T cell-derived signaling pathways.
This article has been cited by other articles:
|
|
 |
|
  D. Carbonnelle, M. Duflos, P. Marchand, C. Chauvet, J.-Y. Petit, and F. Lang A Novel Indole-3-propanamide Exerts Its Immunosuppressive Activity by Inhibiting JAK3 in T Cells J. Pharmacol. Exp. Ther., November 1, 2009; 331(2): 710 - 716. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Breggia, D. M. Wojchowski, and J. Himmelfarb JAK2/Y343/STAT5 signaling axis is required for erythropoietin-mediated protection against ischemic injury in primary renal tubular epithelial cells Am J Physiol Renal Physiol, December 1, 2008; 295(6): F1689 - F1695. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. Salahudeen, N. Haider, J. Jenkins, M. Joshi, H. Patel, H. Huang, M. Yang, and H. Zhe Antiapoptotic properties of erythropoiesis-stimulating proteins in models of cisplatin-induced acute kidney injury Am J Physiol Renal Physiol, June 1, 2008; 294(6): F1354 - F1365. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. Tyner, D. K. Walters, S. G. Willis, M. Luttropp, J. Oost, M. Loriaux, H. Erickson, A. S. Corbin, T. O'Hare, M. C. Heinrich, et al. RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia Blood, February 15, 2008; 111(4): 2238 - 2245. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Fujinaka, K. Takane, H. Yamashita, and R. C. Vasavada Lactogens Promote Beta Cell Survival through JAK2/STAT5 Activation and Bcl-XL Upregulation J. Biol. Chem., October 19, 2007; 282(42): 30707 - 30717. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kim, H. S. Kim, K. W. Chung, S. H. Oh, J. W. Yun, S.-H. Im, M.-K. Lee, K.-W. Kim, and M.-S. Lee Essential Role for Signal Transducer and Activator of Transcription-1 in Pancreatic {beta}-Cell Death and Autoimmune Type 1 Diabetes of Nonobese Diabetic Mice Diabetes, October 1, 2007; 56(10): 2561 - 2568. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Ratthe, M. Pelletier, S. Chiasson, and D. Girard Molecular mechanisms involved in interleukin-4-induced human neutrophils: expression and regulation of suppressor of cytokine signaling J. Leukoc. Biol., May 1, 2007; 81(5): 1287 - 1296. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Bao, S. Devi, J. Bowen-Shauver, S. Ferguson-Gottschall, L. Robb, and G. Gibori The Role of Interleukin-11 in Pregnancy Involves Up-Regulation of {alpha}2-Macroglobulin Gene through Janus Kinase 2-Signal Transducer and Activator of Transcription 3 Pathway in the Decidua Mol. Endocrinol., December 1, 2006; 20(12): 3240 - 3250. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Mansour, F. G. Pereira, E. P. Araujo, M. E. C. Amaral, J. Morari, N. R. Ferraroni, D. S. Ferreira, I. Lorand-Metze, and L. A. Velloso Leptin Inhibits Apoptosis in Thymus through a Janus Kinase-2-Independent, Insulin Receptor Substrate-1/Phosphatidylinositol-3 Kinase-Dependent Pathway Endocrinology, November 1, 2006; 147(11): 5470 - 5479. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Samardzija, A. Wenzel, S. Aufenberg, M. Thiersch, C. Reme, and C. Grimm Differential role of Jak-STAT signaling in retinal degenerations FASEB J, November 1, 2006; 20(13): 2411 - 2413. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. R. Gross, A. K. Hsu, and G. J. Gross The JAK/STAT pathway is essential for opioid-induced cardioprotection: JAK2 as a mediator of STAT3, Akt, and GSK-3beta Am J Physiol Heart Circ Physiol, August 1, 2006; 291(2): H827 - H834. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Maggio, J. M. Guralnik, D. L. Longo, and L. Ferrucci Interleukin-6 in aging and chronic disease: a magnificent pathway. J. Gerontol. A Biol. Sci. Med. Sci., June 1, 2006; 61(6): 575 - 584. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Yu, H. Zeng, M. Vijay-Kumar, A. S. Neish, D. Merlin, S. V. Sitaraman, and A. T. Gewirtz STAT Signaling Underlies Difference between Flagellin-induced and Tumor Necrosis Factor-{alpha}-induced Epithelial Gene Expression J. Biol. Chem., August 20, 2004; 279(34): 35210 - 35218. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Xi, Q. Zhang, K. F. Dyer, E. C. Lerner, T. E. Smithgall, W. E. Gooding, J. Kamens, and J. R. Grandis Src Kinases Mediate STAT Growth Pathways in Squamous Cell Carcinoma of the Head and Neck J. Biol. Chem., August 22, 2003; 278(34): 31574 - 31583. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. L. Molinero, M. B. Fuertes, L. Fainboim, G. A. Rabinovich, and N. W. Zwirner Up-regulated expression of MICA on activated T lymphocytes involves Lck and Fyn kinases and signaling through MEK1/ERK, p38 MAP kinase, and calcineurin J. Leukoc. Biol., June 1, 2003; 73(6): 815 - 822. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. H. Wang, X. Y. Yang, X. Zhang, K. Mihalic, W. Xiao, and W. L. Farrar The cis Decoy against the Estrogen Response Element Suppresses Breast Cancer Cells via Target Disrupting c-fos not Mitogen-activated Protein Kinase Activity Cancer Res., May 1, 2003; 63(9): 2046 - 2051. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. V. Stein, S. F. Soriano, C. M'rini, C. Nombela-Arrieta, G. G. de Buitrago, J. M. Rodriguez-Frade, M. Mellado, J.-P. Girard, and C. Martinez-A. CCR7-mediated physiological lymphocyte homing involves activation of a tyrosine kinase pathway Blood, January 1, 2003; 101(1): 38 - 44. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Burdelya, R. Catlett-Falcone, A. Levitzki, F. Cheng, L. B. Mora, E. Sotomayor, D. Coppola, J. Sun, S. Sebti, W. S. Dalton, et al. Combination Therapy with AG-490 and Interleukin 12 Achieves Greater Antitumor Effects than Either Agent Alone Mol. Cancer Ther., September 1, 2002; 1(11): 893 - 899. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. An, G. W. Nelson, L. Wang, S. Donfield, J. J. Goedert, J. Phair, D. Vlahov, S. Buchbinder, W. L. Farrar, W. Modi, et al. Modulating influence on HIV/AIDS by interacting RANTES gene variants PNAS, July 23, 2002; 99(15): 10002 - 10007. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. F. Skinnider and T. W. Mak The role of cytokines in classical Hodgkin lymphoma Blood, May 29, 2002; 99(12): 4283 - 4297. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Y. Yang, L. H. Wang, K. Mihalic, W. Xiao, T. Chen, P. Li, L. M. Wahl, and W. L. Farrar Interleukin (IL)-4 Indirectly Suppresses IL-2 Production by Human T Lymphocytes via Peroxisome Proliferator-activated Receptor gamma Activated by Macrophage-derived 12/15-Lipoxygenase Ligands J. Biol. Chem., February 1, 2002; 277(6): 3973 - 3978. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Stepkowski, R. A. Erwin-Cohen, F. Behbod, M.-E. Wang, X. Qu, N. Tejpal, Z. S. Nagy, B. D. Kahan, and R. A. Kirken Selective inhibitor of Janus tyrosine kinase 3, PNU156804, prolongs allograft survival and acts synergistically with cyclosporine but additively with rapamycin Blood, January 15, 2002; 99(2): 680 - 689. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kirito, K. Nakajima, T. Watanabe, M. Uchida, M. Tanaka, K. Ozawa, and N. Komatsu Identification of the human erythropoietin receptor region required for Stat1 and Stat3 activation Blood, January 1, 2002; 99(1): 102 - 110. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. B. Han, S. H. Park, Y. J. Jeon, Y. K. Kim, H. M. Kim, and K. H. Yang Prodigiosin Blocks T Cell Activation by Inhibiting Interleukin-2Ralpha Expression and Delays Progression of Autoimmune Diabetes and Collagen-Induced Arthritis J. Pharmacol. Exp. Ther., November 1, 2001; 299(2): 415 - 425. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Frasor, U. Barkai, L. Zhong, A. T. Fazleabas, and G. Gibori PRL-Induced ER{alpha} Gene Expression Is Mediated by Janus Kinase 2 (Jak2) While Signal Transducer and Activator of Transcription 5b (Stat5b) Phosphorylation Involves Jak2 and a Second Tyrosine Kinase Mol. Endocrinol., November 1, 2001; 15(11): 1941 - 1952. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Y. Lee and K. E. Sullivan Gamma Interferon and Lipopolysaccharide Interact at the Level of Transcription To Induce Tumor Necrosis Factor Alpha Expression Infect. Immun., May 1, 2001; 69(5): 2847 - 2852. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Sun, J. E. Layton, A. Elefanty, and G. J. Lieschke Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL-expressing cells, demonstrating synergy between AG490 and STI571 Blood, April 1, 2001; 97(7): 2008 - 2015. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Behbod, R. A. Erwin-Cohen, M.-E. Wang, B. W. Trawick, X. Qu, R. Verani, B. D. Kahan, S. M. Stepkowski, and R. A. Kirken Concomitant Inhibition of Janus Kinase 3 and Calcineurin-Dependent Signaling Pathways Synergistically Prolongs the Survival of Rat Heart Allografts J. Immunol., March 15, 2001; 166(6): 3724 - 3732. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. B. Lilly, M. Zemskova, A. E. Frankel, J. Salo, and A. S. Kraft Distinct domains of the human granulocyte-macrophage colony-stimulating factor receptor {alpha} subunit mediate activation of Jak/Stat signaling and differentiation Blood, March 15, 2001; 97(6): 1662 - 1670. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Prigent-Tessier, U. Barkai, C. Tessier, H. Cohen, and G. Gibori Characterization of a Rat Uterine Cell Line, UIII Cells: Prolactin (PRL) Expression and Endogenous Regulation of PRL-Dependent Genes; Estrogen Receptor {{beta}}, {{alpha}}2-Macroglobulin, and Decidual PRL Involving the Jak2 and Stat5 Pathway Endocrinology, March 1, 2001; 142(3): 1242 - 1250. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Chklovskaia, C. Nissen, L. Landmann, C. Rahner, O. Pfister, and A. Wodnar-Filipowicz Cell-surface trafficking and release of flt3 ligand from T lymphocytes is induced by common cytokine receptor {gamma}-chain signaling and inhibited by cyclosporin A Blood, February 15, 2001; 97(4): 1027 - 1034. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Kirken, R. A. Erwin, L. Wang, Y. Wang, H. Rui, and W. L. Farrar Functional Uncoupling of the Janus Kinase 3-Stat5 Pathway in Malignant Growth of Human T Cell Leukemia Virus Type 1-Transformed Human T Cells J. Immunol., November 1, 2000; 165(9): 5097 - 5104. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J O'Shea, R. Visconti, T. P Cheng, and M. Gadina Jaks and Stats as therapeutic targets Ann Rheum Dis, November 1, 2000; 59(90001): i115 - 118. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. H. Wang, R. A. Kirken, X. Y. Yang, R. A. Erwin, L. DaSilva, C.-R. Yu, and W. L. Farrar Selective disruption of interleukin 4 autocrine-regulated loop by a tyrosine kinase inhibitor restricts activity of T-helper 2 cells Blood, June 15, 2000; 95(12): 3816 - 3822. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Chen, L. H. Wang, and W. L. Farrar Interleukin 6 Activates Androgen Receptor-mediated Gene Expression through a Signal Transducer and Activator of Transcription 3-dependent Pathway in LNCaP Prostate Cancer Cells Cancer Res., April 1, 2000; 60(8): 2132 - 2135. [Abstract] [Full Text]
|
|
|
|
|
|
X. Y. Yang, L. H. Wang, T. Chen, D. R. Hodge, J. H. Resau, L. DaSilva, and W. L. Farrar Activation of Human T Lymphocytes Is Inhibited by Peroxisome Proliferator-activated Receptor gamma (PPARgamma ) Agonists. PPARgamma CO-ASSOCIATION WITH TRANSCRIPTION FACTOR NFAT J. Biol. Chem., February 18, 2000; 275(7): 4541 - 4544. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-i. Kagami, H. Nakajima, K. Kumano, K. Suzuki, A. Suto, K. Imada, H. W. Davey, Y. Saito, K. Takatsu, W. J. Leonard, et al. Both Stat5a and Stat5b are required for antigen-induced eosinophil and T-cell recruitment into the tissue Blood, February 15, 2000; 95(4): 1370 - 1377. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. S. Zong, J. Chan, D. E. Levy, C. Horvath, H. B. Sadowski, and L.-H. Wang Mechanism of STAT3 Activation by Insulin-like Growth Factor I Receptor J. Biol. Chem., May 12, 2000; 275(20): 15099 - 15105. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Kristof, J. Marks-Konczalik, and J. Moss Mitogen-activated Protein Kinases Mediate Activator Protein-1-dependent Human Inducible Nitric-oxide Synthase Promoter Activation J. Biol. Chem., March 9, 2001; 276(11): 8445 - 8452. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Xiao, L. Wang, X. Yang, T. Chen, D. Hodge, P. F. Johnson, and W. Farrar CCAAT/Enhancer-binding Protein beta Mediates Interferon-gamma -induced p48 (ISGF3-gamma ) Gene Transcription in Human Monocytic Cells J. Biol. Chem., June 22, 2001; 276(26): 23275 - 23281. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. H. Wang, X. Y. Yang, K. Mihalic, W. Xiao, D. Li, and W. L. Farrar Activation of Estrogen Receptor Blocks Interleukin-6-inducible Cell Growth of Human Multiple Myeloma Involving Molecular Cross-talk between Estrogen Receptor and STAT3 Mediated by Co-regulator PIAS3 J. Biol. Chem., August 17, 2001; 276(34): 31839 - 31844. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
